Celsion Corp. (NASDAQ:CLSN) Chairman Michael H. Tardugno bought 10,000 shares of the company’s stock in a transaction dated Friday, October 7th. The shares were purchased at an average price of $1.14 per share, with a total value of $11,400.00. Following the transaction, the chairman now owns 143,021 shares of the company’s stock, valued at $163,043.94. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.

Shares of Celsion Corp. (NASDAQ:CLSN) opened at 1.13 on Friday. The company has a 50-day moving average price of $1.21 and a 200-day moving average price of $1.34. Celsion Corp. has a 12-month low of $1.04 and a 12-month high of $2.31. The company’s market cap is $29.17 million.

Celsion Corp. (NASDAQ:CLSN) last issued its quarterly earnings results on Monday, August 15th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.02. Celsion Corp. had a negative return on equity of 103.07% and a negative net margin of 3,966.14%. On average, analysts predict that Celsion Corp. will post ($0.83) earnings per share for the current year.

Insider Buying and Selling by Quarter for Celsion Corp. (NASDAQ:CLSN)

A number of equities research analysts have recently weighed in on the company. Maxim Group restated a “buy” rating and set a $9.00 target price on shares of Celsion Corp. in a research report on Monday, July 11th. HC Wainwright restated a “buy” rating and set a $3.00 target price on shares of Celsion Corp. in a research report on Tuesday, July 12th.

A hedge fund recently raised its stake in Celsion Corp. stock. Sabby Management LLC increased its position in Celsion Corp. (NASDAQ:CLSN) by 7,986.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,519,365 shares of the company’s stock after buying an additional 1,500,576 shares during the period. Sabby Management LLC owned approximately 6.48% of Celsion Corp. worth $1,930,000 at the end of the most recent reporting period. 15.19% of the stock is currently owned by hedge funds and other institutional investors.

About Celsion Corp.

Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).

5 Day Chart for NASDAQ:CLSN

Receive News & Ratings for Celsion Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion Corp. and related companies with MarketBeat.com's FREE daily email newsletter.